Epion Therapeutics is developing a minimally invasive treatment for keratoconus that can bring early intervention to millions of patients globally. Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without mechanical or chemical disruption of the epithelium, allowing for a rapid return to normal activities. Our Phase 2 clinical study completed the enrollment of 2,258 patients. The study showed that EpiSmart-treated keratoconus patients showed statistically significant improvements in best- corrected distance vision at 6 and 12 months post-treatment. Of the patients with keratoconus who were followed for 12 months, over 80% had stable or improved vision following EpiSmart treatment. Epion launched its Phase 3 studies in the fall of 2023. Last year, we announced raising a $32 million Series A funding round led by AXA IM Global Health plus a syndicate of individual investors, including leading cornea specialists.